Plain-English translation of NCT03843463 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether escitalopram, an antidepressant medication, can help boost the effectiveness of speech therapy in people recovering from a stroke that affects language. The medication works by increasing a brain chemical called serotonin, which may help the brain rewire itself and recover language abilities faster. Researchers will compare people who take this medication alongside speech therapy to those who receive speech therapy with a placebo (a dummy pill).
After a stroke, many people lose the ability to speak or find words, a condition called aphasia. While speech therapy helps, recovery is often slow and incomplete. Scientists think this medication might enhance the brain's natural ability to heal and rewire itself, potentially making speech therapy much more effective.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would take a daily pill (either the medication or a placebo) for 90 days after your stroke, while also receiving standard speech and language therapy. You'll have several clinic visits for brain imaging scans (MRI), a heart test (ECG), blood tests, and assessments of your language abilities. Some visits will include genetic testing to help researchers understand how your brain responds to treatment. The entire study lasts about three months.
AI-generated summary from trial data ยท Aug 15, 2026 ยท Not medical advice
United States